Loading publications…
The last 5 uploaded publications
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Ciara Conduit, Andrisha–Jade Inderjeeth, R.J. Allen, Andrew Martin, Wendy R. Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Scott North, Gavin Marx, Anthony M. Joshua, Lisa G. Horvath, Ray McDermott, Simon Chowdhury, Kim N., Alison Y. Zhang, Martin R. Stockler, Ian D. Davis, Christopher J. Sweeney (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). , DOI: https://doi.org/10.1080/14796694.2024.2440277.
Article63 days ago8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Alison Yan Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin, Thean Hsiang Tan, David Pook, Gavin Marx, Robert Zielinski, Shahneen Sandhu, Alastair Thomson, M. Neil Reaume, Scott North, John McCaffrey, Ray McDermott, Nicola Jane Lawrence, Lisa G. Horvath, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney (2025). 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5090.
Article63 days agoRadiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).
Ian D. Davis, Andrew Martin, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Andrisha Jade Inderjeeth, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher J. Sweeney (2024). Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).. , 42(4_suppl), DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.151.
Article63 days agoTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N., Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sébastien J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Joanne Edwards, Peter C.C. Fong, Alvin Tan, Simon Chowdhury (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. , 24(4), DOI: https://doi.org/10.1016/s1470-2045(23)00063-3.
Article63 days agoPrognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).
Ronan Andrew Mc Laughlin, Hayley Thomas, Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5079.
Article63 days ago